कृपया अन्य खोज का प्रयास करें
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Pratik S. Multani | 57 | 2018 | Independent Director |
Valerie Harding-Start | 64 | 2019 | Independent Director |
James A. Bristol | 77 | 2018 | Independent Director |
John Lo | - | 2022 | Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board |
Alexander Whitman Casdin | 56 | 2018 | Independent Director |
Julie Hambleton | 66 | 2021 | Independent Director |
Karen Cichowski | - | - | Scientific Advisory Board Member |
Pablo Rodriguez-Viciana | - | - | Scientific Advisory Board Member |
Bruce D. Roth | - | - | Member of R&D Advisory Board |
Linda Robertson | - | - | Member of R&D Advisory Board |
Kevan M. Shokat | - | - | Scientific Advisory Board Member |
Jonathan E. Lim | 52 | 2018 | Co-Founder, Chairman & CEO |
Gregory Cosma | - | - | Member of R&D Advisory Board |
David Matthews | 81 | - | Member of R&D Advisory Board |
Paul G. Pearson | 63 | - | Member of R&D Advisory Board |
James L. Freddo | 69 | - | Member of R&D Advisory Board |
Ryan B. Corcoran | - | - | Scientific Advisory Board Member |
George Daniel Demetri | 67 | - | Scientific Advisory Board Member |
Stephen C. Blacklow | - | - | Scientific Advisory Board Member |
Jane Chang | - | - | Member of R&D Advisory Board |
Jean I. Liu | 56 | 2022 | Independent Director |
Michael D. Varney | 66 | 2020 | Chairman of Research & Development, Scientific Advisory Board Member and Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है